Stem Cell Therapy International has completed its merger with South Korean firm Histostem in a deal that will allow it to run Histostem as its wholly owned unit. Stem Cell Therapy, a provider of biological supplies containing new stem cell product lines, plans to operate under the name AmStem.

Related Summaries